Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Trends, Growth Report 2033

Middle East And Africa Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

Market Size in USD Million

CAGR : 6.90 %

Bar chart comparing the Middle East And Africa Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market size in 2025 - 63.58 and 2033 - 102.78, highlighting the projected market growth.

USD 63.58 Million USD 102.78 Million 2025 2033

Forecast Period	2026 - 2033
Market Size (Base Year)	USD 63.58 Million
Market Size (Forecast Year)	USD 102.78 Million
CAGR	6.90 %
Major Markets Players	Stanford Health Care (U.S.) HOSPIRA (Now part of Pfizer) (U.S.) Aurora Health Care (U.S.) Takeda Pharmaceutical Company Limited (Japan) Fresenius Kabi AG (Germany)

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size

The Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market size was valued at USD 63.58 Million in 2025 and is expected to reach USD 102.78 Million by 2033, at a CAGR of 6.9% during the forecast period. The market is witnessing steady growth due to the increasing prevalence of short bowel syndrome associated with intestinal failure, rising awareness regarding rare gastrointestinal disorders, and continuous advancements in specialized nutritional and pharmacological therapies. Growing adoption of multidisciplinary treatment approaches, coupled with improved diagnostic capabilities and enhanced patient management strategies, is further supporting market expansion.

The increasing burden of intestinal resections resulting from conditions such as Crohn’s disease, mesenteric ischemia, trauma, congenital abnormalities, and cancer-related surgeries has significantly contributed to the demand for Type 1 SBS-IF treatments. Healthcare providers are increasingly utilizing parenteral nutrition, enteral nutrition support, and glucagon-like peptide-2 (GLP-2) analog therapies to improve intestinal adaptation, reduce complications, and enhance patient quality of life.

Key Market Trends & Analysis

Saudi Arabia dominated the Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment market with the largest revenue share of 19.42% in 2025, supported by advanced healthcare infrastructure, strong reimbursement policies, and widespread access to specialized intestinal rehabilitation centers.
The Nutritional Support Therapy segment led the market with a 41.73% share in 2025, driven by its critical role in maintaining hydration, nutrient absorption, and overall patient management during intestinal recovery.
United Arab Emirates is expected to be the fastest-growing country at a CAGR of 7.5% from 2026 to 2033, fueled by improving healthcare accessibility, increasing awareness of rare gastrointestinal disorders, and growing investments in advanced treatment options across emerging economies.
Emerging and Advanced Therapies are the fastest-growing treatment modality segment, projected to register a CAGR of 7.2%, reflecting increasing adoption of innovative biologics, GLP-2 analogs, and regenerative treatment approaches aimed at reducing long-term parenteral nutrition dependence.
The Core SBS-IF Market segment dominates the market attribution category with a 56.80% revenue share in 2025, supported by the substantial patient population requiring specialized and continuous intestinal failure management.
The Acute Phase (Type 1 SBS-IF) segment accounted for the largest share of 48.29% in 2025, driven by the immediate need for intensive nutritional support, fluid management, and clinical intervention following major intestinal resection or injury.
The Adaptation Phase segment is anticipated to be the fastest-growing phase category, registering a CAGR of 7.1% during the forecast period, owing to increasing focus on therapies that enhance intestinal adaptation, improve nutrient absorption, and support long-term patient recovery.

Market Size & Forecast

Middle East and Africa Market Value (2025): USD 63.58 Million
Expected Market Value (2033): USD 102.78 Million
Forecast CAGR (2026–2033): 6.9%
Fastest Growing Country: United Arab Emirates

Report Scope and Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Segmentation

Attributes	Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Key Market Insights
Segments Covered	By Treatment Modality: Nutritional Support Therapy, Pharmacological Therapy, Surgical & Interventional Treatment, and Emerging & Advanced Therapies By Market Attribution: Core SBS-IF Market, SBS-IF Attributable Market, and Adjacent / Non-Specific Market By Disease Management Phase: Acute Phase (Type 1 SBS-IF), Adaptation Phase, and Recovery Phase By Patient Type: Adult and Pediatric By Route of Administration: Intravenous, Subcutaneous, Oral, and Enteral By Intravenous Type: PN and Injectables By End User: Hospitals (Acute Care), Home Care (HPN Programs), ICU Settings, Specialty GI Centers, and Pediatric Specialty Hospitals By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy, and Online Pharmacy
Countries Covered	Middle East and Africa · Saudi Arabia · South Africa · Egypt · Israel · United Arab Emirates · Kuwait · Oman · Qatar · Bahrain · Rest of Middle East and Africa
Key Market Players	· Stanford Health Care (U.S.) · Nestle Health Science (Switzerland) · HOSPIRA (Now part of Pfizer) (U.S.) · Aurora Health Care (U.S.) · Takeda Pharmaceutical Company Limited (Japan) · Fresenius Kabi AG (Germany) · Grifols (Spain) · Abbott Laboratories (U.S.) · Shandong Qidu Pharmaceutical Co., Ltd. (China) · Ferring Pharmaceuticals (Switzerland) · UF Health (U.S.) · Baxter International INC (U.S.) · VectivBio AG (Switzerland) · Hikma Pharmaceuticals PLC (U.K.) · NUTRICIA (DANONE) (Netherlands) · Amsino International, Inc. (U.S.) · Braun Melsungen AG (Germany) · ContinuumRx (U.S.) · JEDUX PARENTERAL PRIVATE LIMITED (India) · Beverly Hills Digestive Care (U.S.) · Choice Parenteral Nutrition LLC (U.S.) · Integrated Care Systems (U.S.) · Camvitaa (India) · Eclipse Regenesis (U.S.) · LABORATOIRE DIELEN (France) · Vision Parenteral Pvt. Ltd. (India) · Aculife Healthcare (India) · Nutrego (Poland) · Pharmko, Inc. (U.S.) · Infusion Solutions (U.S.) · UF Health (U.S.) · Integrated Care Systems (U.S.) · Choice Parenteral Nutrition LLC (U.S.) · ContinuumRx (U.S.) · NUTRICIA NORTH AMERICA (U.S.) · Napo Therapeutics (U.S.) · a Moog company (U.S.) · ICU Medical, Inc. (U.S.) · Eclipse Regenesis (U.S.) · Puerto Life Sciences Pvt. Ltd (India) · Bausch Health Companies (Canada)
Market Opportunities	· Advancements in Regenerative Medicine · Expansion of Home-Based Nutritional Care
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Trend: Complex Multidisciplinary Patient Management

Advancements in regenerative medicine and intestinal rehabilitation are creating strong growth opportunities for the Middle East and Africa Type 1 SBS-IF treatment market. Researchers and healthcare institutions are increasingly focusing on therapies that can improve intestinal adaptation, regenerate damaged intestinal tissue, and reduce long-term dependence on parenteral nutrition. According to studies supported by the National Institutes of Health, regenerative approaches such as stem cell therapy, tissue engineering, and intestinal transplantation research are showing promising results in improving nutrient absorption and restoring bowel function in severe SBS-IF patients. Several academic hospitals and specialized intestinal rehabilitation centers in North America and Middle East and Africa are also expanding multidisciplinary treatment programs that combine GLP-2 therapies, advanced nutritional support, surgery, and personalized rehabilitation plans. These developments are helping improve patient survival and quality of life while opening new long-term treatment opportunities beyond traditional nutritional management.

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Dynamics

Key Market Driver: Rising SBS-If Patient Population

The rising patient population suffering from Short Bowel Syndrome with Intestinal Failure (SBS-IF) is becoming one of the major growth drivers for the Middle East and Africa type 1 SBS-IF treatment market. SBS-IF mainly develops when a large portion of the small intestine is removed through surgery, reducing the body’s ability to absorb nutrients and fluids properly. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the condition most commonly occurs after small bowel resection surgeries performed for diseases such as Crohn’s disease, intestinal cancers, trauma, bowel obstruction, ischemia, and congenital intestinal disorders. The growing incidence of inflammatory bowel diseases, especially Crohn’s disease, is significantly contributing to the increase in intestinal surgeries worldwide. NIDDK also states that severe Crohn’s disease patients often require repeated bowel resections, which raises the long-term risk of developing SBS-IF.

Key Restraint/Challenge: High Cost Of SBS-If Treatment

The high cost of SBS-IF treatment remains one of the biggest restraints for the Middle East and Africa type 1 SBS-IF treatment market. patients with short bowel syndrome with intestinal failure often require lifelong parenteral nutrition, frequent hospital monitoring, specialized intestinal rehabilitation, and advanced biologic therapies such as teduglutide. According to the U.S. Food and Drug Administration and Takeda treatment information, GLP-2 therapies like GATTEX can cost nearly USD 400,000–USD 500,000 annually per patient in the United States, making treatment financially difficult for many families and healthcare systems. In addition to drug costs, SBS-IF patients often need central venous catheter care, nutritional supplements, regular blood testing, and repeated hospital admissions due to infections or dehydration complications. These long-term medical expenses place a major burden on both patients and insurance providers, especially in countries where reimbursement coverage for rare diseases is still limited.

Key Market Opportunity: Expansion of Advanced Biologic and GLP-2 Analog Therapies

The Middle East and Africa Type 1 SBS-IF treatment market presents significant growth opportunities driven by continuous advancements in therapeutic and nutritional management approaches. Increasing adoption of innovative biologics, particularly GLP-2 analog therapies, is creating new avenues for improving intestinal adaptation and reducing dependence on parenteral nutrition. The growing focus on personalized nutrition plans and multidisciplinary care is enhancing patient outcomes and expanding treatment accessibility. Emerging economies offer substantial potential due to improving healthcare infrastructure, greater awareness of rare gastrointestinal disorders, and rising healthcare expenditure. Additionally, ongoing research in regenerative medicine, stem-cell-based therapies, and intestinal tissue engineering may transform future treatment paradigms. Expanding home-based care models and remote monitoring solutions are also expected to improve long-term disease management and patient quality of life

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Scope

The market is segmented on the basis of treatment modality, market attribution, disease management phase, patient type, route of administration, intravenous type, end user, and distribution channel.

By Treatment Modality

On the basis of treatment modality, the Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into nutritional support therapy, pharmacological therapy, surgical & interventional treatment, and emerging & advanced therapies. The nutritional support therapy segment dominated the largest market revenue share of 41.73% in 2025, driven by the rising dependence on parenteral and enteral nutrition for long-term SBS-IF management across hospitals and home healthcare settings. Increasing adoption of home parenteral nutrition (HPN) programs, advancements in clinical nutrition formulations, and growing focus on improving patient quality of life continue to support segment growth. Rising prevalence of gastrointestinal surgeries and chronic intestinal disorders further accelerates demand for nutritional rehabilitation therapies. Improved reimbursement support and increasing awareness regarding chronic intestinal failure management are also contributing to higher segment adoption across Middle East and Africa.

The emerging & advanced therapies segment is anticipated to witness the fastest CAGR of 7.2% from 2026 to 2033, fueled by the growing adoption of biologics, GLP-2 analog therapies, and innovative intestinal rehabilitation approaches. Increasing research activities focused on rare gastrointestinal diseases and rising investments in advanced SBS-IF treatment development are expanding the therapeutic landscape. Pharmaceutical companies are increasingly focusing on precision medicine and targeted therapies to reduce dependency on parenteral nutrition and improve intestinal function. Supportive regulatory frameworks, expanding clinical trials, and advancements in personalized treatment solutions are further contributing to rapid segment growth across the Middle East and Africa Type 1 SBS-IF Treatment Market.

By Market Attribution

On the basis of market attribution, the Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into core SBS-IF market, SBS-IF attributable market, and adjacent / non-specific market. The core SBS-IF market segment dominated the largest market revenue share of 56.80% in 2025, driven by the increasing diagnosis of intestinal failure cases requiring specialized nutritional support and long-term clinical management. Growing adoption of parenteral nutrition therapies, rising awareness regarding chronic intestinal disorders, and expanding access to specialized gastrointestinal treatment centers continue to support segment growth. Increasing healthcare expenditure on rare gastrointestinal diseases and advancements in nutritional rehabilitation programs are further accelerating market demand. Improved reimbursement policies and growing integration of home healthcare solutions are also contributing to strong segment adoption across Middle East and Africa.

The SBS-IF attributable market segment is anticipated to witness the fastest CAGR of 7.1% from 2026 to 2033, fueled by the increasing recognition of SBS-IF-related complications and the growing need for supportive therapeutic interventions. Rising prevalence of gastrointestinal surgeries, intestinal resections, and chronic digestive disorders is driving demand for attributable treatment solutions and associated nutritional care programs. Healthcare providers are increasingly focusing on early disease management and multidisciplinary treatment approaches to improve patient outcomes. Continuous advancements in biologic therapies, clinical nutrition support, and patient monitoring technologies are further contributing to segment expansion. Increasing investments in rare disease treatment infrastructure and supportive government initiatives are expected to drive rapid growth across the Middle East and Africa Type 1 SBS-IF Treatment Market.

By Disease Management Phase

On the basis of disease management phase, the Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into acute phase (Type 1 SBS-IF), adaptation phase, and recovery phase. The acute phase (Type 1 SBS-IF) segment dominated the largest market revenue share of 48.29% in 2025, driven by the increasing number of patients requiring immediate nutritional intervention and intensive clinical management following intestinal surgeries and severe gastrointestinal complications. Rising dependence on parenteral nutrition support, growing hospitalization rates, and increasing demand for specialized gastrointestinal care continue to support segment growth. Advancements in intensive nutritional therapy programs and improved monitoring technologies are further enhancing treatment outcomes. Increasing awareness regarding early SBS-IF diagnosis and management is also contributing to strong segment adoption across Middle East and Africa.

The adaptation phase segment is anticipated to witness the fastest CAGR of 7.1% from 2026 to 2033, fueled by the growing focus on intestinal rehabilitation and long-term nutritional optimization strategies. Increasing adoption of biologic therapies, personalized nutrition programs, and advanced rehabilitation approaches is supporting improved intestinal adaptation and reduced dependency on parenteral nutrition. Healthcare providers are increasingly emphasizing multidisciplinary treatment models to improve patient recovery and quality of life. Continuous advancements in clinical nutrition formulations and home healthcare management solutions are further contributing to segment expansion. Rising investments in gastrointestinal rehabilitation infrastructure and supportive treatment innovations are expected to drive rapid growth across the Middle East and Africa Type 1 SBS-IF Treatment Market.

By Patient Type

On the basis of patient type, the Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into adult and pediatric. The adult segment dominated the largest market revenue share of 71.62% in 2025, driven by the increasing prevalence of gastrointestinal disorders, intestinal resections, and chronic digestive complications among the adult population. Rising dependence on long-term parenteral nutrition therapies, increasing hospitalization rates, and growing adoption of home healthcare nutritional support programs continue to support segment growth. Advancements in nutritional formulations and integrated gastrointestinal care approaches are further improving treatment outcomes. Increasing awareness regarding chronic intestinal failure management and supportive reimbursement frameworks are also contributing to strong segment adoption across Middle East and Africa.

The pediatric segment is anticipated to witness the fastest CAGR of 7.1% from 2026 to 2033, fueled by the rising incidence of congenital intestinal disorders, neonatal gastrointestinal complications, and pediatric intestinal failure cases. Increasing focus on specialized pediatric nutritional support therapies and advanced intestinal rehabilitation programs is driving segment expansion. Healthcare providers are increasingly adopting personalized treatment strategies and multidisciplinary care models to improve long-term pediatric patient outcomes. Continuous advancements in pediatric parenteral nutrition formulations and supportive homecare solutions are further contributing to market growth. Rising investments in pediatric gastrointestinal treatment infrastructure and increasing awareness regarding early intervention strategies are expected to accelerate segment demand across the Middle East and Africa Type 1 SBS-IF Treatment Market.

By Route of Administration

On the basis of route of administration, the Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into intravenous, subcutaneous, oral, and enteral. The intravenous segment dominated the largest market revenue share of 49.61% in 2025, driven by the increasing dependence on parenteral nutrition therapies for immediate and long-term SBS-IF management. Intravenous administration remains essential for patients with severe intestinal absorption limitations and acute nutritional deficiencies. Rising adoption of home parenteral nutrition (HPN) programs, advancements in infusion technologies, and growing availability of specialized nutritional formulations continue to support segment growth. Increasing hospitalization rates related to gastrointestinal disorders and supportive reimbursement frameworks are further contributing to strong segment adoption across Middle East and Africa.

The subcutaneous segment is anticipated to witness the fastest CAGR of 7.2% from 2026 to 2033, fueled by the growing adoption of biologic therapies and advanced injectable treatment options for SBS-IF management. Increasing preference for minimally invasive drug delivery methods, improved patient convenience, and reduced hospital dependency are driving segment expansion. Healthcare providers are increasingly utilizing subcutaneous administration for targeted therapies and long-term disease management approaches. Continuous advancements in biologic formulations, self-administration devices, and homecare treatment programs are further contributing to market growth. Rising investments in innovative gastrointestinal therapies and increasing awareness regarding patient-centric treatment solutions are expected to accelerate segment demand across the Middle East and Africa Type 1 SBS-IF Treatment Market.

By End User

On the basis of end user, the Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into hospitals (acute care), home care (HPN programs), ICU settings, specialty GI centers, and pediatric specialty hospitals. The hospitals (acute care) segment dominated the largest market revenue share of 38.59% in 2025, driven by the increasing hospitalization rates associated with intestinal failure, gastrointestinal surgeries, and severe nutritional deficiencies. Hospitals remain the primary treatment settings for intensive nutritional support, acute SBS-IF management, and multidisciplinary gastrointestinal care. Rising adoption of advanced parenteral nutrition therapies, increasing availability of specialized care teams, and growing investments in hospital-based nutritional rehabilitation programs continue to support segment growth. Supportive reimbursement structures and improved clinical infrastructure are further contributing to strong segment adoption across Middle East and Africa.

The home care (HPN programs) segment is anticipated to witness the fastest CAGR of 7.4% from 2026 to 2033, fueled by the growing adoption of home parenteral nutrition solutions for long-term SBS-IF management. Increasing preference for home-based treatment approaches, improved patient convenience, and reduced hospitalization costs are driving segment expansion. Healthcare providers are increasingly emphasizing home healthcare programs to improve quality of life and long-term nutritional management outcomes. Continuous advancements in portable infusion systems, remote patient monitoring technologies, and personalized nutritional therapies are further contributing to market growth. Rising awareness regarding chronic intestinal failure management and expanding home healthcare infrastructure are expected to accelerate segment demand across the Middle East and Africa Type 1 SBS-IF Treatment Market.

By Distribution Channel

On the basis of distribution channel, the Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is segmented into hospital pharmacy, specialty pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the largest market revenue share of 46.62% in 2025, driven by the increasing hospitalization rates associated with intestinal failure and the rising administration of parenteral nutrition therapies in acute care settings. Hospital pharmacies remain the primary distribution channels for specialized nutritional formulations, biologic therapies, and intensive SBS-IF treatment products. Growing availability of multidisciplinary gastrointestinal care programs and increasing demand for clinically supervised treatment solutions continue to support segment growth. Supportive reimbursement frameworks and expanding hospital infrastructure are further contributing to strong segment adoption across Middle East and Africa.

The specialty pharmacy segment is anticipated to witness the fastest CAGR of 7.2% from 2026 to 2033, fueled by the increasing demand for advanced biologic therapies, personalized nutritional formulations, and long-term SBS-IF treatment management solutions. Rising preference for specialized pharmaceutical support services and improved access to rare disease treatment products are driving segment expansion. Healthcare providers are increasingly collaborating with specialty pharmacies to ensure continuous patient monitoring, therapy management, and home-based treatment support. Continuous advancements in specialty drug distribution networks and patient assistance programs are further contributing to market growth. Increasing awareness regarding chronic intestinal failure management and growing adoption of patient-centric treatment approaches are expected to accelerate segment demand across the Middle East and Africa Type 1 SBS-IF Treatment Market.

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

Saudi Arabia dominated the Middle East Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market, accounting for the largest revenue share of 19.42% in 2025. The country's leading position is supported by its well-developed healthcare infrastructure, increasing diagnosis rates of rare gastrointestinal disorders, and strong access to advanced parenteral nutrition therapies and specialized treatment centers. Rising healthcare expenditure, government initiatives to improve rare disease management, and the presence of major hospitals equipped with multidisciplinary care teams have further contributed to market growth. Additionally, growing awareness among healthcare professionals and patients regarding SBS-IF treatment options continues to drive demand across Saudi Arabia.

South Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

The U.K. Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is projected to expand at a substantial CAGR throughout the forecast period, driven by increasing awareness regarding chronic intestinal failure management, rising adoption of advanced nutritional support therapies, and growing healthcare investments in rare gastrointestinal diseases. Increasing demand for home-based parenteral nutrition programs, expanding multidisciplinary care approaches, and growing use of biologic treatment solutions are supporting market growth. In addition, supportive healthcare policies and the presence of advanced clinical nutrition infrastructure are further accelerating the adoption of SBS-IF treatment solutions across hospitals and specialty care centers.

Egypt Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

The Egypt Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market is expected to witness significant growth during the forecast period, driven by rising prevalence of gastrointestinal disorders, increasing adoption of clinical nutrition therapies, and growing focus on long-term intestinal rehabilitation programs. Expanding investments in healthcare infrastructure, increasing use of advanced parenteral nutrition formulations, and growing awareness regarding patient-centric SBS-IF management approaches are contributing to market expansion. Furthermore, supportive reimbursement frameworks and increasing availability of specialized gastrointestinal treatment facilities are encouraging the adoption of SBS-IF treatment solutions across hospital and homecare settings.

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Share

The Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market industry is primarily led by well-established companies, including:

Nestle Health Science (Switzerland)

Stanford Health Care (U.S.)
HOSPIRA (Now part of Pfizer) (U.S.)
Aurora Health Care (U.S.)
Takeda Pharmaceutical Company Limited (Japan)
Fresenius Kabi AG (Germany)
Grifols (Spain)
Abbott Laboratories (U.S.)
Shandong Qidu Pharmaceutical Co., Ltd. (China)
Ferring Pharmaceuticals (Switzerland)
UF Health (U.S.)
Baxter International INC (U.S.)
VectivBio AG (Switzerland)
Hikma Pharmaceuticals PLC (U.K.)
NUTRICIA (DANONE) (Netherlands)
Amsino International, Inc. (U.S.)
Braun Melsungen AG (Germany)
ContinuumRx (U.S.)
JEDUX PARENTERAL PRIVATE LIMITED (India)
Beverly Hills Digestive Care (U.S.)
Choice Parenteral Nutrition LLC (U.S.)
Integrated Care Systems (U.S.)
Camvitaa (India)
Eclipse Regenesis (U.S.)
LABORATOIRE DIELEN (France)
Vision Parenteral Pvt. Ltd. (India)
Aculife Healthcare (India)
Nutrego (Poland)
Pharmko, Inc. (U.S.)
Infusion Solutions (U.S.)
UF Health (U.S.)
Integrated Care Systems (U.S.)
Choice Parenteral Nutrition LLC (U.S.)
ContinuumRx (U.S.)
NUTRICIA NORTH AMERICA (U.S.)
Napo Therapeutics (U.S.)
a Moog company (U.S.)
ICU Medical, Inc. (U.S.)
Eclipse Regenesis (U.S.)
Puerto Life Sciences Pvt. Ltd (India)
Bausch Health Companies (Canada)

Latest Developments in Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market

In January 2026, Fresenius Kabi has introduced a new dosage form of its biosimilar ustekinumab (Otulfi), offering a 45 mg/0.5 mL single-dose vial. This addition expands the available presentation range of Otulfi, which is a biosimilar to Janssen’s Stelara (ustekinumab). With this update, Fresenius Kabi now provides multiple dosage forms and strengths of the reference product, improving flexibility for physicians and treatment options for patients. This strengthens Fresenius Kabi’s biosimilar portfolio by improving product flexibility.
In March 2025, Baxter International has introduced the IV Verify Line Labeling System, an automated solution designed to replace handwritten IV labels with barcode-based, standardized labeling at hospitals. The system helps clinicians print clear, color-coded adhesive labels for IV tubing, improving accuracy and reducing medication errors at the bedside. It strengthens Baxter’s position in hospital infusion technology.e
In February 2026, Nestlé Health Science announced the inclusion of its nutritional products under an exceptional reimbursement framework within Portugal’s public health system, allowing eligible products to be partially or fully covered by the National Health Service. This regulatory decision strengthens patient access to clinical nutrition solutions and supports integration of medical nutrition into formal healthcare reimbursement pathways. This will benefit the company by improving product accessibility, expanding prescription-based demand, and reinforcing its position within the reimbursed clinical nutrition market.

SKU-76250

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 DBMR MARKET POSITION GRID

2.7 VENDOR SHARE ANALYSIS

2.8 MULTIVARIATE MODELING

2.9 PRODUCT TYPE TIMELINE CURVE

2.1 MARKET APPLICATION COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.1.1 INTRODUCTION

4.1.2 POLITICAL ANALYSIS

4.1.3 ECONOMIC ANALYSIS

4.1.4 SOCIAL ANALYSIS

4.1.5 TECHNOLOGICAL ANALYSIS

4.1.6 ENVIRONMENTAL ANALYSIS

4.1.7 LEGAL ANALYSIS

4.1.8 CONCLUSION

4.2 PORTER’S FIVE FORCES ANALYSIS

4.2.1 INTRODUCTION

4.2.2 INTENSITY OF COMPETITIVE RIVALRY (HIGH)

4.2.3 BARGAINING POWER OF BUYERS – HIGH

4.2.4 THREAT OF NEW ENTRANTS – MODERATE

4.2.5 THREAT OF SUBSTITUTE PRODUCTS – MODERATE

4.2.6 BARGAINING POWER OF SUPPLIERS – MODERATE

4.2.7 CONCLUSION

4.3 COMPANY EVALUATION QUADRANT

4.4 PATIENT FUNNEL METHODOLOGY (MANDATORY MODEL)

4.4.1 A BOTTOM-UP PATIENT FUNNEL WILL BE CONSTRUCTED

4.4.1.1 TOTAL SBS POPULATION

4.4.1.2 SBS-IF POPULATION

4.4.1.3 DIAGNOSED SBS-IF PATIENTS

4.4.1.4 TREATED SBS-IF PATIENTS

4.4.1.5 THERAPY-SPECIFIC PATIENT POOLS

4.4.1.6 THIS ENSURES PATIENT NUMBERS ARE DIRECTLY ESTIMATED, NOT INFERRED FROM MARKET SIZE

4.4.1.7 MIDDLE EAST AND AFRICA PATIENT FUNNEL SEGMENTATION

4.4.1.8 TOTAL SBS POPULATION

4.4.1.9 ADULT SBS

4.4.1.10 PEDIATRIC SBS

4.4.1.11 SBS-IF POPULATION

4.4.1.12 TYPE 1 SBS-IF (ACUTE)

4.4.1.13 TYPE 2 SBS-IF (PROLONGED ACUTE)

4.4.1.14 TYPE 3 SBS-IF (CHRONIC)

4.4.1.15 DIAGNOSED PATIENT POPULATION

4.4.1.16 DIAGNOSED – HOSPITAL-BASED

4.4.1.17 DIAGNOSED – OUTPATIENT FOLLOW-UP

4.4.1.18 UNDIAGNOSED / MISCLASSIFIED

4.4.1.19 TREATED PATIENT POPULATION

4.4.1.20 ACTIVELY TREATED PATIENTS

4.4.1.21 UNTREATED / SUPPORTIVE-ONLY

4.4.2 TREATMENT-SPECIFIC PATIENT SEGMENTATION (CRITICAL)

4.4.2.1 PN-DEPENDENT PATIENT POPULATION (CORE SEGMENT)

4.4.2.2 FULLY PN-DEPENDENT

4.4.2.3 PARTIALLY PN-DEPENDENT

4.4.2.4 ICU PN-DEPENDENT (TYPE 1 ACUTE)

4.4.2.5 HOME PN-DEPENDENT

4.4.2.6 GLP-2 ANALOGUE TREATED PATIENTS

4.4.2.7 INCLUDES PATIENTS RECEIVING TEDUGLUTIDE

4.4.2.8 PIPELINE THERAPIES (E.G., APRAGLUTIDE)

4.4.2.9 SUB-SEGMENTATION

4.4.2.10 PN-DEPENDENT RECEIVING GLP-2

4.4.2.11 PN-WEANING PATIENTS

4.4.2.12 PEDIATRIC VS ADULT

4.4.2.13 SUPPORTIVE PHARMACOTHERAPY PATIENTS (ATTRIBUTABLE)

4.4.2.14 ANTI-DIARRHEAL USERS

4.4.2.15 PPI USERS

4.4.2.16 ANTIBIOTIC (SIBO) PATIENTS

4.4.2.17 MICRONUTRIENT-DEPENDENT PATIENTS

4.4.2.18 SURGICAL & TRANSPLANT PATIENTS

4.4.2.19 INTESTINAL LENGTHENING PROCEDURES

4.4.2.20 TRANSPLANT PATIENTS

4.4.2.21 POST-TRANSPLANT SURVIVORS

4.4.3 PATIENT SEGMENTATION BY DEPENDENCY STATUS (HIGHLY IMPORTANT)

4.4.3.1 PN-DEPENDENT POPULATION

4.4.3.2 CORE REVENUE-DRIVING SEGMENT

4.4.3.3 PN-WEANING POPULATION

4.4.3.4 GLP-2 RESPONDERS

4.4.3.5 PN-INDEPENDENT POPULATION

4.4.3.6 MAINTAINED ON ORAL/ENTERAL THERAPY

4.4.4 PATIENT SEGMENTATION BY DISEASE PHASE (TYPE 1 FOCUS)

4.4.4.1 ACUTE PHASE (TYPE 1 SBS-IF)

4.4.4.2 ICU-MANAGED PATIENTS

4.4.4.3 HIGH PN UTILIZATION

4.4.4.4 ADAPTATION PHASE

4.4.4.5 TRANSITION TO ENTERAL NUTRITION

4.4.4.6 INITIATION OF GLP-2 THERAPY

4.4.4.7 RECOVERY / STABILIZATION PHASE

4.4.4.8 REDUCED PN DEPENDENCY

4.4.4.9 LONG-TERM MAINTENANCE

4.4.4.10 PATIENT SEGMENTATION BY CARE SETTING

4.4.4.11 HOSPITAL-BASED PATIENTS

4.4.4.12 ICU

4.4.4.13 SURGICAL WARDS

4.4.4.14 HOME CARE PATIENTS

4.4.4.15 HOME PARENTERAL NUTRITION (HPN)

4.4.4.16 SPECIALTY CENTERS

4.4.4.17 INTESTINAL REHABILITATION CENTERS

4.4.5 PATIENT SEGMENTATION BY DEMOGRAPHICS

4.4.5.1 AGE GROUP

4.4.5.2 NEONATES

4.4.5.3 PEDIATRIC

4.4.5.4 ADULTS

4.4.5.5 GERIATRIC

4.4.5.6 GENDER

4.4.5.7 MALE

4.4.5.8 FEMALE

4.4.6 PATIENT SEGMENTATION BY ETIOLOGY

4.4.6.1 ADULT ETIOLOGY

4.4.6.2 CROHN'S DISEASE

4.4.6.3 MESENTERIC ISCHEMIA

4.4.6.4 SURGICAL RESECTIONS

4.4.6.5 ONCOLOGY-RELATED

4.4.6.6 PEDIATRIC ETIOLOGY

4.4.6.7 NECROTIZING ENTEROCOLITIS (NEC)

4.4.6.8 CONGENITAL DEFECTS (ATRESIA, GASTROSCHISIS)

4.4.7 GEOGRAPHIC PATIENT DISTRIBUTION

4.4.7.1 NORTH AMERICA

4.4.7.2 U.S.

4.4.7.3 CANADA

4.4.7.4 EUROPE

4.4.7.5 GERMANY

4.4.7.6 FRANCE

4.4.7.7 UK

4.4.7.8 ITALY

4.4.7.9 SPAIN

4.4.7.10 ASIA-PAIFIC

4.4.7.11 JAPAN

4.4.7.12 CHINA

4.4.7.13 INDIA

4.4.8 TREATMENT PENETRATION & UTILIZATION RATES

4.4.8.1 PN PENETRATION RATE

4.4.8.2 % OF SBS-IF PATIENTS ON PN

4.4.8.3 GLP-2 PENETRATION RATE

4.4.8.4 % OF ELIGIBLE PATIENTS RECEIVING GLP-2

4.4.8.5 SUPPORTIVE THERAPY PENETRATION

4.4.8.6 ANTI-DIARRHEAL USAGE RATE

4.4.8.7 PPI USAGE RATE

4.4.8.8 PATIENT-LEVEL COST MODELING

4.4.8.9 ANNUAL COST PER PATIENT

4.4.8.10 PN COST (HOSPITAL VS HOME)

4.4.8.11 GLP-2 THERAPY COST

4.4.8.12 SUPPORTIVE THERAPY COST

4.4.9 COST BY PATIENT TYPE

4.4.9.1 PN-DEPENDENT

4.4.9.2 GLP-2 TREATED

4.4.9.3 TRANSPLANT

4.4.9.4 OUTPUT DELIVERABLES (EXCEL – CLIENT CRITICAL)

4.4.9.5 TOTAL SBS-IF PATIENTS (BY COUNTRY)

4.4.9.6 DIAGNOSED VS TREATED PATIENTS

4.4.9.7 PN-DEPENDENT PATIENTS

4.4.9.8 GLP-2 TREATED PATIENTS

4.4.9.9 TREATMENT PENETRATION RATES

4.4.9.10 AVERAGE ANNUAL COST PER THERAPY

4.5 INDUSTRY INSIGHTS

4.5.1 INTRODUCTION

4.5.2 INDUSTRY STRUCTURE OVERVIEW

4.5.3 MICRO AND MACRO ECONOMIC FACTORS

4.5.4 PENETRATION AND GROWTH PROSPECT MAPPING

4.5.5 KEY PRICING STRATEGIES

4.5.6 INTERVIEWS WITH SPECIALISTS

4.5.7 ANALYSIS AND RECOMMENDATION

4.5.8 CONCLUSION

4.6 WAR-DRIVEN DISRUPTION IN PHARMACEUTICAL SUPPLY CHAINS, GEOGRAPHIC FOOTPRINTS, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES

4.6.1 INTRODUCTION

4.6.2 SUPPLY CHAIN RESILIENCE

4.6.2.1 DIVERSIFICATION OF INGREDIENT AND PN/DRUG SUPPLIERS

4.6.2.2 ESTABLISHMENT OF REGIONAL PRODUCTION HUBS

4.6.2.3 STRATEGIC STOCKPILING OF CRITICAL PN BAGS, GLP-2 ANALOGUES, AND MEDICAL DEVICES

4.6.2.4 DEVELOPMENT OF ALTERNATIVE LOGISTICS AND COLD CHAIN ROUTES

4.6.2.5 STRATEGIC PARTNERSHIPS WITH LEADING CDMOS (E.G., CATALENT, LONZA)

4.6.2.6 EXPANSION OF MANUFACTURING, FILL-FINISH, AND PACKAGING CAPABILITIES FOR PN & GLP-2

4.6.3 ENERGY & MANUFACTURING OPERATIONAL COST RISK

4.6.3.1 RISING ENERGY COSTS IN PARENTERAL NUTRITION & DRUG FACILITIES

4.6.3.2 INCREASED COSTS FOR RAW MATERIALS, LIPID EMULSIONS, AND PHARMACEUTICALS

4.6.3.3 LONG-TERM ENERGY PROCUREMENT STRATEGIES FOR PN MANUFACTURERS

4.6.3.4 ADOPTION OF ENERGY-EFFICIENT MANUFACTURING TECHNOLOGIES

4.6.3.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS SYSTEMS

4.6.3.6 INTEGRATION OF RENEWABLE ENERGY IN MANUFACTURING FACILITIES

4.6.4 GEOGRAPHIC FOOTPRINT REASSESSMENT

4.6.4.1 EXPANSION OF MANUFACTURING IN STABLE REGIONS

4.6.4.2 DIVERSIFICATION OF MIDDLE EAST AND AFRICA PN/GLP-2 PRODUCTION SITES

4.6.4.3 RELOCATION OF KEY INPUT/INTERMEDIATE PRODUCTION

4.6.4.4 EXPANSION INTO EMERGING MARKETS WITH HIGH SBS-IF BURDEN

4.6.4.5 ESTABLISHMENT OF REGIONAL COLD CHAIN TRANSIT AND DISTRIBUTION HUBS

4.6.5 SCENARIO PLANNING & RISK MANAGEMENT

4.6.5.1 DEVELOPMENT OF SUPPLY CHAIN CONTINGENCY PLANS

4.6.5.2 MULTI-SOURCE PROCUREMENT STRATEGIES FOR PN/GLP-2

4.6.5.3 GOVERNMENT AND HEALTH AUTHORITY COLLABORATIONS

4.6.5.4 CRISIS-RESPONSE SUPPLY NETWORKS FOR CRITICAL THERAPIES

4.6.5.5 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS IN SBS-IF MARKET

4.6.6 CASH & FINANCIAL PROTECTION

4.6.7 STRENGTHENING CAPITAL RESERVES FOR PN & BIOPHARMA EXPANSION

4.6.7.1 DIVERSIFICATION OF PRODUCT PORTFOLIOS AND REVENUE STREAMS

4.6.7.2 INVESTMENTS IN DOMESTIC PRODUCTION INFRASTRUCTURE

4.6.7.3 GOVERNMENT INCENTIVES AND PUBLIC-PRIVATE PARTNERSHIPS

4.6.7.4 LONG-TERM PROCUREMENT CONTRACTS WITH HEALTHCARE SYSTEMS

4.6.8 DATA PROTECTION

4.6.8.1 DATA PROTECTION FRAMEWORKS FOR CLINICAL AND REAL-WORLD SBS-IF DATA

4.6.8.2 PROTECTION OF CLINICAL TRIAL DATA, PATIENT DATA, AND DRUG DEVELOPMENT

4.6.8.3 SECURE CLOUD INFRASTRUCTURE FOR SBS-IF DATA MANAGEMENT

4.6.8.4 AI-DRIVEN THREAT DETECTION IN MARKET RESEARCH AND PHARMA NETWORKS

4.6.8.5 COMPLIANCE WITH PHARMACEUTICAL DATA REGULATIONS & GXP

4.6.9 NEW BUSINESS AND EMERGING REVENUE OPPORTUNITIES & FUTURE OUTLOOK

4.6.10 CONCLUSION

4.7 EPIDEMIOLOGY

4.7.1 INTRODUCTION

4.7.2 INCIDENCE OF TYPE 1 SBS-IF BY GENDER

4.7.3 TREATMENT RATE

4.7.4 MORTALITY RATE

4.7.5 TREATMENT ADHERENCE AND SWITCH MODEL

4.7.6 PATIENT TREATMENT SUCCESS RATES

4.7.7 CONCLUSION

4.8 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF MARKET

4.9 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – MIDDLE EAST AND AFRICA TYPE 1 SBS-IF MARKET

4.1 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – MIDDLE EAST AND AFRICA TYPE 1 SBS-IF MARKET

4.11 PIPELINE ANALYSIS

4.11.1 INTRODUCTION

4.11.2 CLINICAL TRIALS AND PHASE ANALYSIS

4.11.3 DRUG & BIOTHERAPY PIPELINE

4.11.4 PHASE III CANDIDATES (E.G., APRAGLUTIDE)

4.11.5 PHASE II CANDIDATES (E.G., LONG-ACTING GLP-2)

4.11.6 PHASE I CANDIDATES (EMERGING REGENERATIVE/CELLULAR)

4.11.7 OTHERS (PRE-CLINICAL, EN FORMULATION PIPELINE)

4.11.8 CONCLUSION

4.12 PIPELINE ANALYSIS

4.12.1 INTRODUCTION

4.12.2 TAKEDA PHARMACEUTICAL COMPANY – R&D LEADERSHIP IN INTESTINAL REGENERATION THERAPIES

4.12.3 BAXTER INTERNATIONAL – PARENTERAL NUTRITION AND INFUSION SYSTEM INNOVATION

4.12.4 FRESENIUS KABI AG – CLINICAL NUTRITION AND INJECTABLE THERAPY DEVELOPMENT

4.12.5 NESTLÉ HEALTH SCIENCE – MEDICAL NUTRITION AND GUT ADAPTATION RESEARCH

4.12.6 ABBOTT LABORATORIES – INTEGRATED NUTRITION AND METABOLIC MONITORING SOLUTIONS

4.12.7 CONCLUSION

4.13 MARKETED THERAPY ANALYSIS

4.13.1 INTRODUCTION

4.13.2 DRUG/THERAPY

4.13.2.1 BRAND NAME

4.13.2.2 GENERICS NAME

4.13.3 PHARMACOLOGICAL CLASSIFICATION

4.13.4 PRIMARY INDICATION

4.13.5 MARKET STATUS

4.13.6 MEDICATION TYPE

4.13.7 DOSAGE FORM

4.13.8 DOSAGE AVAILABILITY

4.13.9 PACKAGING TYPE

4.13.10 ROUTE OF ADMINISTRATION

4.13.11 DOSING FREQUENCY

4.13.12 THERAPY INSIGHT

4.13.13 AN OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES, REGULATORY MILESTONES, SAFETY/EFFICACY, MARKET EXCLUSIVITY DATA

4.13.14 FORECAST MARKET OUTLOOK

4.13.14.1 CROSS COMPETITION

4.13.14.2 THERAPEUTIC PORTFOLIO

4.13.14.3 CURRENT DEVELOPMENT SCENARIO

4.13.15 CONCLUSION

4.14 PIPELINE ANALYSIS - MIDDLE EAST AND AFRICA TYPE 1 SBS-IF TREATMENT MARKET

4.14.1 CLINICAL TRIALS AND PHASE ANALYSIS

4.14.2 DRUG AND BIOTHERAPY PIPELINE

4.14.3 PHASE III CANDIDATES

4.14.4 PHASE II CANDIDATES

4.14.5 PHASE I CANDIDATES

4.14.6 OTHERS (PRE-CLINICAL AND RESEARCH STAGE)

4.15 R & D ANALYSIS

4.15.1 COMPARATIVE ANALYSIS

4.15.2 DEVELOPMENTAL LANDSCAPE

4.15.3 INSIGHTS ON REGULATORY MILESTONES

4.15.4 THERAPEUTIC ASSESSMENT

4.15.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

5 HEALTHCARE TARIFFS IMPACT ANALYSIS

5.1 OVERVIEW

5.2 TARIFF STRUCTURES

5.2.1 MIDDLE EAST AND AFRICA VS. REGIONAL TARIFF STRUCTURES

5.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES

5.2.3 ASIA-PACIFIC: GOVERNMENT TARIFFS ON IMPORTED PN/DRUG THERAPIES

5.2.4 EMERGING MARKETS: TARIFF CHALLENGES FOR NUTRITION & BIOLOGICS

5.2.5 MAJOR MARKET UPTAKE

5.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS

5.3.1 IMPORT DUTIES ON PN KITS, GLP-2 VS. GENERICS

5.3.2 IMPACT ON AFFORDABILITY & ACCESS

5.3.3 KEY TRADE AGREEMENTS AFFECTING SBS-IF PRODUCTS

5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS/PATIENTS

5.4.1 COST BURDEN ON HOSPITALS AND FACILITIES

5.4.2 EFFECT ON PATIENT AFFORDABILITY & INSURANCE COVERAGE

5.4.3 ROLE IN MEDICAL TOURISM FOR ADVANCED SBS-IF THERAPIES

5.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS

5.5.1 WTO REGULATIONS

5.5.2 TRADE WARS IMPACT ON SUPPLY CHAIN

5.5.3 FTAS IN REDUCING TARIFFS

5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

6 MARKET ACCESS

6.1 10-YEAR MARKET FORECAST

6.2 CLINICAL TRIAL RECENT UPDATES

6.3 ANNUAL NEW FDA APPROVALS FOR SBS-IF TREATMENTS

6.4 MANUFACTURERS, DISTRIBUTORS, AND DEALS

6.5 MAJOR MARKET UPTAKE

6.6 CURRENT TREATMENT PRACTICES

6.7 IMPACT OF UPCOMING THERAPIES

7 REGULATORY FRAMEWORK–

7.1 INTRODUCTION

7.2 REGULATORY APPROVAL PROCESS

7.3 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

7.4 REGULATORY APPROVAL PATHWAYS

7.5 LICENSING AND REGISTRATION

7.6 POST-MARKETING SURVEILLANCE

7.7 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

7.8 CONCLUSION

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING SBS-IF PATIENT POPULATION

8.1.2 GROWING ADOPTION OF GLP-2 THERAPIES

8.1.3 INCREASING GOVERNMENT & ORPHAN DRUG SUPPORT

8.2 RESTRAINTS

8.2.1 HIGH COST OF SBS-IF TREATMENT

8.2.2 LIMITE.D AWARENESS & DELAYED DIAGNOSIS

8.3 OPPORTUNITIES

8.3.1 COMPLEX MULTIDISCIPLINARY PATIENT MANAGEMENT

8.3.2 STRINGENT REGULATORY APPROVAL PROCESSES

8.4 CHALLENGES

8.4.1 ADVANCEMENTS IN REGENERATIVE MEDICINE

8.4.2 EXPANSION OF HOME-BASED NUTRITIONAL CARE

9 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY

9.1 OVERVIEW

9.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

9.2.1 NUTRITIONAL SUPPORT THERAPY

9.2.2 PHARMACOLOGICAL THERAPY

9.2.3 SURGICAL & INTERVENTIONAL TREATMENT

9.2.4 EMERGING & ADVANCED THERAPIES

9.3 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.3.1 PARENTERAL NUTRITION (PN)

9.3.2 ENTERAL NUTRITION (EN)

9.3.3 PN COMPOSITION

9.4 MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.4.1 HOME PARENTERAL NUTRITION (HPN)

9.4.2 PERIPHERAL PARENTERAL NUTRITION (PPN)

9.4.3 CYCLIC PARENTERAL NUTRITION

9.5 MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.5.1 HOSPITAL-BASED TPN

9.5.2 ICU-BASED TPN

9.6 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

9.6.1 ADULT HPN

9.6.2 PEDIATRIC HPN

9.7 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

9.7.1 LONG-TERM HPN

9.7.2 SHORT-TERM HPN

9.8 MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.8.1 ORAL FEEDING

9.8.2 TUBE FEEDING

9.8.3 FORMULA TYPE

9.9 MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.9.1 NASOGASTRIC (NG)

9.9.2 PEG FEEDING

9.9.3 JEJUNOSTOMY FEEDING

9.1 MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.10.1 POLYMERIC

9.10.2 ELEMENTAL

9.10.3 SEMI-ELEMENTAL

9.11 MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.11.1 MACRONUTRIENTS

9.11.2 ELECTROLYTES & FLUIDS

9.11.3 MICRONUTRIENTS

9.12 MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.12.1 AMINO ACIDS

9.12.2 LIPID EMULSIONS

9.12.3 DEXTROSE

9.13 MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.13.1 VITAMINS

9.13.2 TRACE ELEMENTS

9.14 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.14.1 NORTH AMERICA

9.14.2 EUROPE

9.14.3 ASIA-PACIFIC

9.14.4 MIDDLE EAST AND AFRICA

9.14.5 SOUTH AMERICA

9.15 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.15.1 HORMONAL & INTESTINAL ADAPTATION THERAPY

9.15.2 ANTI-DIARRHEAL THERAPY

9.15.3 ANTI-SECRETORY THERAPY

9.15.4 MICRONUTRIENT SUPPLEMENTATION

9.15.5 ANTI-INFECTIVE THERAPY

9.15.6 BILE ACID & ABSORPTION MODIFIERS

9.16 MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.16.1 GLP-2 ANALOGUES

9.16.2 GROWTH HORMONE THERAPY

9.16.3 IGF-1 & ANALOGUES

9.17 MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.17.1 TEDUGLUTIDE

9.17.2 APRAGLUTIDE (LATE-STAGE)

9.17.3 LONG-ACTING GLP-2 ANALOGUES

9.18 MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

9.18.1 HUMATROPE

9.18.2 NORDITROPIN

9.18.3 GENOTROPIN

9.19 MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.19.1 INCRELEX

9.19.2 OTHERS

9.2 MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.20.1 OPIOID-BASED

9.20.2 NON-OPIOID AGENTS

9.21 MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.21.1 LOPERAMIDE

9.21.2 CODEINE

9.22 MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.22.1 PROTON PUMP INHIBITORS

9.22.2 SOMATOSTATIN ANALOGUES

9.22.3 H2 RECEPTOR ANTAGONISTS

9.23 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.23.1 OMEPRAZOLE

9.23.2 PANTOPRAZOLE

9.23.3 ESOMEPRAZOLE

9.23.4 OTHERS

9.24 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

9.24.1 OCTREOTIDE

9.24.2 OTHERS

9.25 MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.25.1 FAMOTIDINE

9.25.2 OTHERS

9.26 MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.26.1 FAT-SOLUBLE VITAMINS (A, D, E, K)

9.26.2 ELECTROLYTES

9.26.3 VITAMIN B12

9.26.4 MINERAL SUPPLEMENTATION

9.27 MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.27.1 BROAD-SPECTRUM ANTIBIOTICS

9.27.2 SIBO-TARGETED THERAPY

9.28 MIDDLE EAST AND AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.28.1 BILE ACID SEQUESTRANTS

9.28.2 FAT ABSORPTION ENHANCERS

9.29 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.29.1 CHOLESTYRAMINE

9.29.2 COLESEVELAM

9.29.3 OTHERS

9.3 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.30.1 NORTH AMERICA

9.30.2 EUROPE

9.30.3 ASIA-PACIFIC

9.30.4 MIDDLE EAST AND AFRICA

9.30.5 SOUTH AMERICA

9.31 MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.31.1 INTESTINAL LENGTHENING PROCEDURES

9.31.2 OSTOMY & RECONSTRUCTION

9.31.3 INTESTINAL TRANSPLANTATION

9.32 MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.32.1 STEP PROCEDURE

9.32.2 BIANCHI PROCEDURE

9.33 MIDDLE EAST AND AFRICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.33.1 ILEOSTOMY

9.33.2 JEJUNOSTOMY

9.33.3 REVERSAL SURGERY

9.34 MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.34.1 ISOLATED SMALL BOWEL

9.34.2 LIVER + INTESTINE

9.34.3 MULTIVISCERAL TRANSPLANT

9.35 MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.35.1 NORTH AMERICA

9.35.2 EUROPE

9.35.3 ASIA-PACIFIC

9.35.4 MIDDLE EAST AND AFRICA

9.35.5 SOUTH AMERICA

9.36 MIDDLE EAST AND AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.36.1 REGENERATIVE MEDICINE

9.36.2 MICROBIOME-BASED THERAPY

9.36.3 GENE THERAPY

9.37 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.37.1 STEM CELL THERAPY

9.37.2 TISSUE-ENGINEERED INTESTINE

9.38 MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.38.1 PROBIOTICS

9.38.2 FMT

9.39 MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.39.1 ABSORPTIVE FUNCTION TARGETING

9.39.2 MUCOSAL GROWTH MODULATION

9.4 MIDDLE EAST AND AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.40.1 NORTH AMERICA

9.40.2 EUROPE

9.40.3 ASIA-PACIFIC

9.40.4 MIDDLE EAST AND AFRICA

9.40.5 SOUTH AMERICA

10 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION

10.1 OVERVIEW

10.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

10.2.1 CORE SBS-IF MARKET

10.2.2 SBS-IF ATTRIBUTABLE MARKET

10.2.3 ADJACENT / NON-SPECIFIC MARKET

10.3 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.3.1 PARENTERAL NUTRITION

10.3.2 GLP-2 ANALOGUES

10.4 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.4.1 NORTH AMERICA

10.4.2 EUROPE

10.4.3 ASIA-PACIFIC

10.4.4 MIDDLE EAST AND AFRICA

10.4.5 SOUTH AMERICA

10.5 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.5.1 ANTI-DIARRHEALS

10.5.2 PPIS

10.5.3 ANTIBIOTICS

10.6 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.6.1 NORTH AMERICA

10.6.2 EUROPE

10.6.3 ASIA-PACIFIC

10.6.4 MIDDLE EAST AND AFRICA

10.6.5 SOUTH AMERICA

10.7 MIDDLE EAST AND AFRICA ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.7.1 NORTH AMERICA

10.7.2 EUROPE

10.7.3 ASIA-PACIFIC

10.7.4 MIDDLE EAST AND AFRICA

10.7.5 SOUTH AMERICA

11 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE

11.1 OVERVIEW

11.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

11.2.1 ACUTE PHASE (TYPE 1 SBS-IF)

11.2.2 ADAPTATION PHASE

11.2.3 RECOVERY PHASE

11.3 MIDDLE EAST AND AFRICA ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.3.1 NORTH AMERICA

11.3.2 EUROPE

11.3.3 ASIA-PACIFIC

11.3.4 MIDDLE EAST AND AFRICA

11.3.5 SOUTH AMERICA

11.4 MIDDLE EAST AND AFRICA ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.4.1 NORTH AMERICA

11.4.2 EUROPE

11.4.3 ASIA-PACIFIC

11.4.4 MIDDLE EAST AND AFRICA

11.4.5 SOUTH AMERICA

11.5 MIDDLE EAST AND AFRICA RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.5.1 NORTH AMERICA

11.5.2 EUROPE

11.5.3 ASIA-PACIFIC

11.5.4 MIDDLE EAST AND AFRICA

11.5.5 SOUTH AMERICA

12 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

12.2.1 ADULT

12.2.2 PEDIATRIC

12.3 MIDDLE EAST AND AFRICA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.3.1 NORTH AMERICA

12.3.2 EUROPE

12.3.3 ASIA-PACIFIC

12.3.4 MIDDLE EAST AND AFRICA

12.3.5 SOUTH AMERICA

12.4 MIDDLE EAST AND AFRICA PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.4.1 NORTH AMERICA

12.4.2 EUROPE

12.4.3 ASIA-PACIFIC

12.4.4 MIDDLE EAST AND AFRICA

12.4.5 SOUTH AMERICA

13 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

13.2.1 INTRAVENOUS

13.2.2 SUBCUTANEOUS

13.2.3 ORAL

13.2.4 ENTERAL

13.3 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

13.3.1 PN

13.3.2 INJECTABLES

13.4 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.4.1 NORTH AMERICA

13.4.2 EUROPE

13.4.3 ASIA-PACIFIC

13.4.4 MIDDLE EAST AND AFRICA

13.4.5 SOUTH AMERICA

13.5 MIDDLE EAST AND AFRICA SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.5.1 NORTH AMERICA

13.5.2 EUROPE

13.5.3 ASIA-PACIFIC

13.5.4 MIDDLE EAST AND AFRICA

13.5.5 SOUTH AMERICA

13.6 MIDDLE EAST AND AFRICA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.6.1 NORTH AMERICA

13.6.2 EUROPE

13.6.3 ASIA-PACIFIC

13.6.4 MIDDLE EAST AND AFRICA

13.6.5 SOUTH AMERICA

13.7 MIDDLE EAST AND AFRICA ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.7.1 NORTH AMERICA

13.7.2 EUROPE

13.7.3 ASIA-PACIFIC

13.7.4 MIDDLE EAST AND AFRICA

13.7.5 SOUTH AMERICA

14 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

14.2.1 HOSPITALS (ACUTE CARE)

14.2.2 HOME CARE (HPN PROGRAMS)

14.2.3 ICU SETTINGS

14.2.4 PECIALTY GI CENTERS

14.2.5 PEDIATRIC SPECIALTY HOSPITALS

14.3 MIDDLE EAST AND AFRICA HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.3.1 NORTH AMERICA

14.3.2 EUROPE

14.3.3 ASIA-PACIFIC

14.3.4 MIDDLE EAST AND AFRICA

14.3.5 SOUTH AMERICA

14.4 MIDDLE EAST AND AFRICA HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.4.1 NORTH AMERICA

14.4.2 EUROPE

14.4.3 ASIA-PACIFIC

14.4.4 MIDDLE EAST AND AFRICA

14.4.5 SOUTH AMERICA

14.5 MIDDLE EAST AND AFRICA ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.5.1 NORTH AMERICA

14.5.2 EUROPE

14.5.3 ASIA-PACIFIC

14.5.4 MIDDLE EAST AND AFRICA

14.5.5 SOUTH AMERICA

14.6 MIDDLE EAST AND AFRICA SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.6.1 NORTH AMERICA

14.6.2 EUROPE

14.6.3 ASIA-PACIFIC

14.6.4 MIDDLE EAST AND AFRICA

14.6.5 SOUTH AMERICA

14.7 MIDDLE EAST AND AFRICA PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.7.1 NORTH AMERICA

14.7.2 EUROPE

14.7.3 ASIA-PACIFIC

14.7.4 MIDDLE EAST AND AFRICA

14.7.5 SOUTH AMERICA

15 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

15.2.1 HOSPITAL PHARMACY

15.2.2 SPECIALTY PHARMACY

15.2.3 RETAIL PHARMACY

15.2.4 ONLINE PHARMACY

15.3 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.3.1 NORTH AMERICA

15.3.2 EUROPE

15.3.3 ASIA-PACIFIC

15.3.4 MIDDLE EAST AND AFRICA

15.3.5 SOUTH AMERICA

15.4 MIDDLE EAST AND AFRICA SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.4.1 NORTH AMERICA

15.4.2 EUROPE

15.4.3 ASIA-PACIFIC

15.4.4 MIDDLE EAST AND AFRICA

15.4.5 SOUTH AMERICA

15.5 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.5.1 NORTH AMERICA

15.5.2 EUROPE

15.5.3 ASIA-PACIFIC

15.5.4 MIDDLE EAST AND AFRICA

15.5.5 SOUTH AMERICA

16 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION

16.1 MIDDLE EAST AND AFRICA

16.1.1 SAUDI ARABIA

16.1.2 SOUTH AFRICA

16.1.3 EGYPT

16.1.4 ISERAEL

16.1.5 UNITED ARAB EMIRATES

16.1.6 KUWAIT

16.1.7 OMAN

16.1.8 QATAR

16.1.9 BAHRAIN

16.1.10 REST OF MIDDLE EAST AND AFRICA

17 MIDDLE EAST AND AFRICA MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY LANDSCAPE

17.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL

18 SWOT ANALYSIS

19 COMPANY PROFILES

19.1 FRESENIUS KABI

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 BAXTER INTERNATIONAL INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 NESTLÉ HEALTH SCIENCE

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 ABBOTT LABORATORIES

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 MOOG COMPANY

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT/NEWS

19.7 ACULIFE HEALTHCARE

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 AMSINO INTERNATIONAL, INC

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 AURORA HEALTH CARE

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 AMERIPHARMA SPECIALTY CARE.

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 BAUSCH HEALTH COMPANIES INC

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 BEVELRYHILLS DIGESTIVE CARE

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 B. BRAUN SE

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 CAMVITTA

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 CHOICE PARENTERAL NUTRITION LLC

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 CONTINUUMRX

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 FERRING PHARMACEUTICALS

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENT

19.18 GRIFOLS S.A.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 HIKMA PHARMACEUTICALS

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENT

19.2 HOSPIRA (PART OF PFIZER INC.)

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

19.21 HANMI PHARM.CO.,LTD.

19.21.1 COMPANY SNAPSHOT

19.21.2 REVENUE ANALYSIS

19.21.3 PRODUCT PORTFOLIO

19.21.4 RECENT DEVELOPMENT

19.22 ICU MEDICAL, INC.

19.22.1 COMPANY SNAPSHOT

19.22.2 REVENUE ANALYSIS

19.22.3 PRODUCT PORTFOLIO

19.22.4 RECENT DEVELOPMENT

19.23 INFUSION SOLUTIONS

19.23.1 COMPANY SNAPSHOT

19.23.2 PRODUCT PORTFOLIO

19.23.3 RECENT DEVELOPMENT

19.24 INTEGRATED CARE SYSTEMS

19.24.1 COMPANY SNAPSHOT

19.24.2 PRODUCT PORTFOLIO

19.24.3 RECENT DEVELOPMENT

19.25 JEDUX PARENTERAL PRIVATE LIMITED

19.25.1 COMPANY SNAPSHOT

19.25.2 PRODUCT PORTFOLIO

19.25.3 RECENT DEVELOPMENT

19.26 LABORATOIRE DIELEN

19.26.1 COMPANY SNAPSHOT

19.26.2 PRODUCT PORTFOLIO

19.26.3 RECENT DEVELOPMENT

19.27 NAPO THERAPEUTICS.

19.27.1 COMPANY SNAPSHOT

19.27.2 PRODUCT PORTFOLIO

19.27.3 RECENT DEVELOPMENT/NEWS

19.28 NUTREGO

19.28.1 COMPANY SNAPSHOT

19.28.2 PRODUCT PORTFOLIO

19.28.3 RECENT DEVELOPMENT

19.29 NUTRICIA (DANONE GROUP)

19.29.1 COMPANY SNAPSHOT

19.29.2 REVENUE ANALYSIS

19.29.3 PRODUCT PORTFOLIO

19.29.4 RECENT DEVELOPMENT

19.3 NUTRICIA NORTH AMERICA

19.30.1 COMPANY SNAPSHOTS

19.30.2 PRODUCT PORTFOLIO

19.30.3 RECENT DEVELOPMENT

19.31 NUTRISHARE

19.31.1 COMPANY SNAPSHOT

19.31.2 PRODUCT PORTFOLIO

19.31.3 RECENT DEVELOPMENT

19.32 OXTHERA

19.32.1 COMPANY SNAPSHOT

19.32.2 PRODUCT PORTFOLIO

19.32.3 RECENT DEVELOPMENT

19.33 PHARMKO, INC.

19.33.1 COMPANY SNAPSHOT

19.33.2 PRODUCT PORTFOLIO

19.33.3 RECENT DEVELOPMENT

19.34 PUERTO LIFE SCIENCES PVT. LTD.

19.34.1 COMPANY SNAPSHOT

19.34.2 PRODUCT PORTFOLIO

19.34.3 RECENT DEVELOPMENT

19.35 SHANDONG QIDU PHARMACEUTICAL CO., LTD.

19.35.1 COMPANY SNAPSHOT

19.35.2 PRODUCT PORTFOLIO

19.35.3 RECENT DEVELOPMENT

19.36 STANFORD HEALTH CARE

19.36.1 COMPANY SNAPSHOT

19.36.2 PRODUCT PORTFOLIO

19.36.3 RECENT DEVELOPMENT

19.37 UF HEALTH

19.37.1 COMPANY SNAPSHOT

19.37.2 PRODUCT PORTFOLIO

19.37.3 RECENT DEVELOPMENT

19.38 IRONWOOD PHARMACEUTICALS

19.38.1 COMPANY SNAPSHOT

19.38.2 REVENUE ANALYSIS

19.38.3 PRODUCT PORTFOLIO

19.38.4 RECENT DEVELOPMENT

19.39 VISION PARENTERAL

19.39.1 COMPANY SNAPSHOT

19.39.2 PRODUCT PORTFOLIO

19.39.3 RECENT DEVELOPMENT

19.4 ZEALAND PHARMA

19.40.1 COMPANY SNAPSHOT

19.40.2 REVENUE ANALYSIS

19.40.3 PRODUCT PORTFOLIO

19.40.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

List of Table

TABLE 1 TREATMENT RATE OF SBI-IF PATIENTS

TABLE 2 ESTIMATED THERAPY-SPECIFIC PATIENT POOLS

TABLE 3 ESTIMATED FUNNEL PATEGINTS

TABLE 4 KEY INDUSTRY INSIGHTS AND MARKET TRENDS IN THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET

TABLE 5 IMPACT OF WAR-DRIVEN DISRUPTIONS ON THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF TREATMENT MARKET ECOSYSTEM AND INDUSTRY RESPONSE FRAMEWORK

TABLE 6 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF MARKET

TABLE 7 DISTRIBUTION OF OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – MIDDLE EAST AND AFRICA TYPE 1 SBS-IF MARKET

TABLE 8 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – MIDDLE EAST AND AFRICA TYPE 1 SBS-IF MARKET

TABLE 9 PIPELINE LANDSCAPE AND CLINICAL DEVELOPMENT OVERVIEW

TABLE 10 TOP ENTITIES BASED ON R&D GLANCE – MIDDLE EAST AND AFRICA TYPE 1 SBS-IF TREATMENT MARKET

TABLE 11 PRECLINICAL / RESEARCH STAGE VACCINE CANDIDATES

TABLE 12 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 13 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 14 MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 15 MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 16 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 17 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 18 MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 19 MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 20 MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 21 MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 22 MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 23 MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 24 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 25 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 26 MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 27 MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 28 MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 29 MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 30 MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 31 MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 32 MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 33 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 34 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 35 MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 36 MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 37 MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 38 MIDDLE EAST AND AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 39 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 40 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 41 MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 42 MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 43 MIDDLE EAST AND AFRICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 44 MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 45 MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 46 MIDDLE EAST AND AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 47 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 48 MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 49 MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 50 MIDDLE EAST AND AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 51 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 52 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 53 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 54 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 55 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 56 MIDDLE EAST AND AFRICA ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 57 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 58 MIDDLE EAST AND AFRICA ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 59 MIDDLE EAST AND AFRICA ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 60 MIDDLE EAST AND AFRICA RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 61 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 62 MIDDLE EAST AND AFRICA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 63 MIDDLE EAST AND AFRICA PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 64 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 65 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 66 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 67 MIDDLE EAST AND AFRICA SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 68 MIDDLE EAST AND AFRICA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 69 MIDDLE EAST AND AFRICA ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 70 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 71 MIDDLE EAST AND AFRICA HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 72 MIDDLE EAST AND AFRICA HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 73 MIDDLE EAST AND AFRICA ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 74 MIDDLE EAST AND AFRICA SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 75 MIDDLE EAST AND AFRICA PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 76 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 77 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 78 MIDDLE EAST AND AFRICA SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 79 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 80 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

TABLE 81 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 82 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 83 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 84 MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 85 MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 86 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 87 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 88 MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 89 MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 90 MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 91 MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 92 MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 93 MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 94 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 95 MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 96 MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 97 MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 98 MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 99 MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 100 MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 101 MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 102 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 103 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 104 MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 105 MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 106 MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 107 MIDDLE EAST AND AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 109 MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 110 MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 111 MIDDLE EAST AND AFRICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 112 MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 113 MIDDLE EAST AND AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 114 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 115 MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 116 MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 117 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 118 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 119 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 120 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 121 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 122 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 123 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 124 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 125 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 126 USD THOUSAND

TABLE 127 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 128 SAUDI ARABIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 129 SAUDI ARABIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 130 SAUDI ARABIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 131 SAUDI ARABIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 132 SAUDI ARABIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 133 SAUDI ARABIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 134 SAUDI ARABIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 135 SAUDI ARABIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 136 SAUDI ARABIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 137 SAUDI ARABIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 138 SAUDI ARABIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 139 SAUDI ARABIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 140 SAUDI ARABIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 141 SAUDI ARABIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 142 SAUDI ARABIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 143 SAUDI ARABIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 144 SAUDI ARABIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 145 SAUDI ARABIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 146 SAUDI ARABIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 147 SAUDI ARABIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 148 SAUDI ARABIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 149 SAUDI ARABIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 150 SAUDI ARABIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 151 SAUDI ARABIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 152 SAUDI ARABIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 153 SAUDI ARABIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 SAUDI ARABIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 155 SAUDI ARABIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 156 SAUDI ARABIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 157 SAUDI ARABIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 158 SAUDI ARABIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 159 SAUDI ARABIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 160 SAUDI ARABIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 161 SAUDI ARABIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 162 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 163 SAUDI ARABIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 164 SAUDI ARABIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 165 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 166 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 167 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 168 SAUDI ARABIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 169 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 170 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 171 USD THOUSAND

TABLE 172 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 173 SOUTH AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 174 SOUTH AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 175 SOUTH AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 SOUTH AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 177 SOUTH AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 178 SOUTH AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 179 SOUTH AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 180 SOUTH AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 181 SOUTH AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 182 SOUTH AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 183 SOUTH AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 184 SOUTH AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 185 SOUTH AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 186 SOUTH AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 187 SOUTH AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 188 SOUTH AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 189 SOUTH AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 190 SOUTH AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 191 SOUTH AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 192 SOUTH AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 193 SOUTH AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 194 SOUTH AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 195 SOUTH AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 196 SOUTH AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 197 SOUTH AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 198 SOUTH AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 199 SOUTH AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 200 SOUTH AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 201 SOUTH AFRICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 202 SOUTH AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 203 SOUTH AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 204 SOUTH AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 205 SOUTH AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 206 SOUTH AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 207 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 208 SOUTH AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 209 SOUTH AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 210 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 211 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 212 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 213 SOUTH AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 214 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 215 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 216 USD THOUSAND

TABLE 217 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 218 EGYPT NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 219 EGYPT PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 220 EGYPT TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 221 EGYPT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 222 EGYPT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 223 EGYPT ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 224 EGYPT TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 225 EGYPT FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 226 EGYPT PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 227 EGYPT MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 228 EGYPT MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 EGYPT PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 230 EGYPT HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 231 EGYPT GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 232 EGYPT GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 233 EGYPT IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 234 EGYPT ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 235 EGYPT OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 236 EGYPT ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 237 EGYPT PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 238 EGYPT SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 239 EGYPT H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 240 EGYPT MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 241 EGYPT ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 242 EGYPT BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 243 EGYPT BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 244 EGYPT SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 245 EGYPT INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 246 EGYPT OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 247 EGYPT INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 248 EGYPT EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 249 EGYPT REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 250 EGYPT MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 251 EGYPT GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 252 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 253 EGYPT CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 254 EGYPT SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 255 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 256 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 257 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 258 EGYPT INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 259 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 260 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 261 USD THOUSAND

TABLE 262 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 263 ISRAEL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 264 ISRAEL PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 265 ISRAEL TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 266 ISRAEL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 267 ISRAEL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 268 ISRAEL ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 269 ISRAEL TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 270 ISRAEL FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 271 ISRAEL PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 272 ISRAEL MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 273 ISRAEL MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 274 ISRAEL PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 275 ISRAEL HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 276 ISRAEL GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 277 ISRAEL GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 278 ISRAEL IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 279 ISRAEL ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 280 ISRAEL OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 281 ISRAEL ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 282 ISRAEL PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 283 ISRAEL SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 284 ISRAEL H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 285 ISRAEL MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 286 ISRAEL ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 287 ISRAEL BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 288 ISRAEL BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 289 ISRAEL SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 290 ISRAEL INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 291 ISRAEL OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 292 ISRAEL INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 293 ISRAEL EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 294 ISRAEL REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 295 ISRAEL MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 ISRAEL GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 297 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 298 ISRAEL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 299 ISRAEL SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 300 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 301 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 302 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 303 ISRAEL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 304 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 305 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 306 USD THOUSAND

TABLE 307 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 308 UNITED ARAB EMIRATES NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 309 UNITED ARAB EMIRATES PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 310 UNITED ARAB EMIRATES TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 311 UNITED ARAB EMIRATES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 312 UNITED ARAB EMIRATES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 313 UNITED ARAB EMIRATES ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 314 UNITED ARAB EMIRATES TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 315 UNITED ARAB EMIRATES FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 316 UNITED ARAB EMIRATES PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 317 UNITED ARAB EMIRATES MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 318 UNITED ARAB EMIRATES MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 319 UNITED ARAB EMIRATES PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 320 UNITED ARAB EMIRATES HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 321 UNITED ARAB EMIRATES GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 322 UNITED ARAB EMIRATES GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 323 UNITED ARAB EMIRATES IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 324 UNITED ARAB EMIRATES ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 325 UNITED ARAB EMIRATES OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 326 UNITED ARAB EMIRATES ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 327 UNITED ARAB EMIRATES PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 328 UNITED ARAB EMIRATES SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 329 UNITED ARAB EMIRATES H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 330 UNITED ARAB EMIRATES MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 331 UNITED ARAB EMIRATES ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 332 UNITED ARAB EMIRATES BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 333 UNITED ARAB EMIRATES BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 334 UNITED ARAB EMIRATES SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 335 UNITED ARAB EMIRATES INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 336 UNITED ARAB EMIRATES OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 337 UNITED ARAB EMIRATES INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 338 UNITED ARAB EMIRATES EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 339 UNITED ARAB EMIRATES REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 340 UNITED ARAB EMIRATES MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 341 UNITED ARAB EMIRATES GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 342 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 343 UNITED ARAB EMIRATES CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 344 UNITED ARAB EMIRATES SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 345 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 346 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 347 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 348 UNITED ARAB EMIRATES INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 349 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 350 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 351 USD THOUSAND

TABLE 352 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 353 KUWAIT NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 354 KUWAIT PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 355 KUWAIT TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 356 KUWAIT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 357 KUWAIT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 358 KUWAIT ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 359 KUWAIT TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 360 KUWAIT FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 361 KUWAIT PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 362 KUWAIT MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 363 KUWAIT MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 364 KUWAIT PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 365 KUWAIT HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 366 KUWAIT GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 367 KUWAIT GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 368 KUWAIT IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 369 KUWAIT ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 370 KUWAIT OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 371 KUWAIT ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 372 KUWAIT PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 373 KUWAIT SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 374 KUWAIT H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 375 KUWAIT MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 376 KUWAIT ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 377 KUWAIT BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 378 KUWAIT BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 KUWAIT SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 380 KUWAIT INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 381 KUWAIT OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 382 KUWAIT INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 383 KUWAIT EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 384 KUWAIT REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 385 KUWAIT MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 386 KUWAIT GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 387 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 388 KUWAIT CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 389 KUWAIT SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 390 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 391 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 392 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 393 KUWAIT INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 394 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 395 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 396 USD THOUSAND

TABLE 397 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 398 OMAN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 399 OMAN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 400 OMAN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 401 OMAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 402 OMAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 403 OMAN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 404 OMAN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 405 OMAN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 406 OMAN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 407 OMAN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 408 OMAN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 409 OMAN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 410 OMAN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 411 OMAN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 412 OMAN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 413 OMAN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 414 OMAN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 415 OMAN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 416 OMAN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 417 OMAN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 418 OMAN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 419 OMAN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 420 OMAN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 421 OMAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 422 OMAN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 423 OMAN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 424 OMAN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 425 OMAN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 426 OMAN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 427 OMAN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 428 OMAN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 429 OMAN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 430 OMAN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 431 OMAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 432 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 433 OMAN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 434 OMAN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 435 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 436 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 437 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 438 OMAN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 439 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 440 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 441 USD THOUSAND

TABLE 442 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 443 QATAR NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 444 QATAR PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 445 QATAR TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 446 QATAR HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 447 QATAR HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 448 QATAR ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 449 QATAR TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 450 QATAR FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 451 QATAR PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 452 QATAR MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 453 QATAR MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 454 QATAR PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 455 QATAR HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 456 QATAR GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 457 QATAR GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 458 QATAR IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 459 QATAR ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 460 QATAR OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 461 QATAR ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 462 QATAR PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 463 QATAR SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 464 QATAR H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 465 QATAR MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 466 QATAR ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 467 QATAR BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 468 QATAR BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 469 QATAR SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 470 QATAR INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 471 QATAR OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 472 QATAR INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 473 QATAR EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 474 QATAR REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 475 QATAR MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 476 QATAR GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 477 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 478 QATAR CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 479 QATAR SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 480 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 481 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 482 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 483 QATAR INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 484 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 485 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 486 USD THOUSAND

TABLE 487 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 488 BAHRAIN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 489 BAHRAIN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 490 BAHRAIN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 491 BAHRAIN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 492 BAHRAIN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 493 BAHRAIN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 494 BAHRAIN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 495 BAHRAIN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 496 BAHRAIN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 497 BAHRAIN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 498 BAHRAIN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 499 BAHRAIN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 500 BAHRAIN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 501 BAHRAIN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 502 BAHRAIN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 503 BAHRAIN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 504 BAHRAIN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 505 BAHRAIN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 506 BAHRAIN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 507 BAHRAIN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 508 BAHRAIN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 509 BAHRAIN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 510 BAHRAIN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 511 BAHRAIN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 512 BAHRAIN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 513 BAHRAIN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 514 BAHRAIN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 515 BAHRAIN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 516 BAHRAIN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 517 BAHRAIN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 518 BAHRAIN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 519 BAHRAIN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 520 BAHRAIN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 521 BAHRAIN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 522 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 523 BAHRAIN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 524 BAHRAIN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 525 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 526 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 527 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 528 BAHRAIN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 529 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 530 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 531 USD THOUSAND

TABLE 532 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 533 REST OF MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 534 REST OF MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 535 REST OF MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 536 REST OF MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 537 REST OF MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 538 REST OF MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 539 REST OF MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 540 REST OF MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 541 REST OF MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 542 REST OF MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 543 REST OF MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 544 REST OF MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 545 REST OF MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 546 REST OF MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 547 REST OF MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 548 REST OF MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 549 REST OF MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 550 REST OF MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 551 REST OF MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 552 REST OF MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 553 REST OF MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 554 REST OF MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 555 REST OF MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 556 REST OF MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 557 REST OF MIDDLE EAST AND AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 558 REST OF MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 559 REST OF MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 560 REST OF MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 561 REST OF MIDDLE EAST AND AFRICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 562 REST OF MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 563 REST OF MIDDLE EAST AND AFRICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 564 REST OF MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 565 REST OF MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 566 REST OF MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 567 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 568 REST OF MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 569 REST OF MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 570 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 571 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 572 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 573 REST OF MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 574 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 575 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

List of Figure

FIGURE 1 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: MULTIVARIVATE MODELING

FIGURE 10 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: PRODUCT TYPE TIMELINE CURVE

FIGURE 11 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: APPLICATION COVERAGE GRID

FIGURE 12 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 13 FOUR SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY (2025)

FIGURE 14 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 RISING SBS-IF PATIENT POPULATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET DURING THE FORECAST PERIOD OF 2026 TO 2033.

FIGURE 16 NUTRITIONAL SUPPORT THERAPY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET IN 2026 & 2033

FIGURE 17 STRATEGIC DECISIONS

FIGURE 18 PESTEL ANALYSIS

FIGURE 19 DROC ANALYSIS

FIGURE 20 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY TREATMENT MODALITY, 2025

FIGURE 21 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY MARKET ATTRIBUTION, 2025

FIGURE 22 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISEASE MANAGEMENT PHASE, 2025

FIGURE 23 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY PATIENT TYPE, 2025

FIGURE 24 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025

FIGURE 25 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY END USER, 2025

FIGURE 26 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025

FIGURE 27 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 28 MIDDLE EAST AND AFRICA MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)

View Detailed Information

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the current size of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

The Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market was valued at USD 63.58 million in 2025 and is projected to reach USD 102.78 million by 2033, growing at a CAGR of 6.9% from 2026 to 2033.

What is the expected growth rate of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

The Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is expected to grow at a CAGR of 6.9% during the forecast period of 2026 to 2033, driven by the increasing prevalence of short bowel syndrome, rising adoption of advanced nutritional and pharmacological therapies, and growing awareness of intestinal rehabilitation programs.

What are the key growth drivers of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

The key growth drivers of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market include the rising prevalence of intestinal failure associated with bowel resections and increasing adoption of specialized nutritional support therapies. Market growth is further supported by advancements in biologic treatments, expanding intestinal rehabilitation programs, and growing investments in rare disease research and patient care.

Which segment dominates the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

The Nutritional Support Therapy segment dominated the Type 1 SBS-IF treatment market, accounting for a 41.73% revenue share in 2025. Its leadership is attributed to its essential role in maintaining hydration, nutrient absorption, and metabolic stability, making it the cornerstone of SBS-IF patient management across acute and recovery phases.

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East And Africa Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

CAGR : 6.90 %

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size

Report Scope and Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Segmentation

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Dynamics

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Scope

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Share

Latest Developments in Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

What is the current size of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

What is the expected growth rate of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

What are the key growth drivers of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Which segment dominates the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Industry Related Reports

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East And Africa Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

CAGR : 6.90 %

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size

Report Scope and Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Segmentation

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Dynamics

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Scope

Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Share

Latest Developments in Middle East and Africa Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

What is the current size of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

What is the expected growth rate of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

What are the key growth drivers of the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Which segment dominates the Middle East and Africa Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Industry Related Reports

Browse Related Pages